Protein lysine methyltransferase SMYD3 is involved in tumorigenesis through regulation of HER2 homodimerization

Smyd3 Is a Transcriptional Potentiator of Multiple Cancer-Promoting Genes and Required for Liver and Colon Cancer Development

(2016) Michalis E. Sarris et al.   CANCER CELL

A SMYD3 Small-Molecule Inhibitor Impairing Cancer Cell Growth

(2015) Alessia Peserico et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Upregulated SMYD3 promotes bladder cancer progression by targeting BCLAF1 and activating autophagy

(2015) Bing Shen et al.   TUMOR BIOLOGY

Molecular architecture of the ErbB2 extracellular domain homodimer

(2015) Shi Hu et al.   Oncotarget

ERBB Receptors: From Oncogene Discovery to Basic Science to Mechanism-Based Cancer Therapeutics

(2014) Carlos L. Arteaga et al.   CANCER CELL

SMYD3 links lysine methylation of MAP3K2 to Ras-driven cancer

(2014) Pawel K. Mazur et al.   NATURE

SMYD3 overexpression was a risk factor in the biological behavior and prognosis of gastric carcinoma

(2014) Yong Liu et al.   TUMOR BIOLOGY

Critical role of lysine 134 methylation on histone H2AX for γ-H2AX production and DNA repair

(2014) Kenbun Sone et al.   Nature Communications

Peptide Level Immunoaffinity Enrichment Enhances Ubiquitination Site Identification on Individual Proteins

(2013) Veronica G. Anania et al.   MOLECULAR & CELLULAR PROTEOMICS

Histone Lysine Methyltransferase SETD8 Promotes Carcinogenesis by Deregulating PCNA Expression

(2012) M. Takawa et al.   CANCER RESEARCH

HER2 stabilizes EGFR and itself by altering autophosphorylation patterns in a manner that overcomes regulatory mechanisms and promotes proliferative and transformation signaling

(2012) Z Hartman et al.   ONCOGENE

Dysregulation of PRMT1 and PRMT6, Type I arginine methyltransferases, is involved in various types of human cancers

(2010) Masanori Yoshimatsu et al.   INTERNATIONAL JOURNAL OF CANCER